Table 1

Baseline Characteristics of the Study Population

Everolimus-Eluting Stent
(n = 1,390)
Sirolimus-Eluting Stent
(n = 1,384)
p Value
Age, yrs64.2 ± 10.964.0 ± 10.80.68
Men1,055 (75.9)1,041 (75.2)0.68
Diabetes mellitus194/1,390 (14.0)196/1,384 (14.2)0.88
Arterial hypertension689/1,215 (56.7)649/1,207 (53.8)0.15
Hypercholesterolemia866/1,218 (71.1)859/1,208 (71.1)1.00
Current smoker344/1,178 (29.2)353/1,162 (30.4)0.53
Body mass index, kg/m227.5 ± 4.727.4 ± 4.40.43
Previous myocardial infarction276/1,223 (22.6)259/1,214 (21.3)0.46
Previous percutaneous coronary intervention264/1,227 (21.5)250/1,214 (20.6)0.58
Previous coronary artery bypass grafting118/1,227 (9.6)97/1,214 (8.0)0.16
Indication for percutaneous coronary intervention0.46
 ST-segment elevation myocardial infarction122 (8.8)145 (10.5)
 Non–ST-segment elevation myocardial infarction or unstable angina458 (32.9)453 (32.7)
 Stable angina773 (55.6)754 (54.4)
 Other37 (2.7)32 (2.3)
No. of lesions treated1,8051,779
Target lesions per patient0.85
 11,062 (76.4)1,072 (77.5)
 2256 (18.4)244 (17.6)
 360 (4.3)54 (3.9)
 >312 (0.9)14 (1.0)
No. per patient1.3 (0.6)1.3 (0.6)0.56
No. of stents
 Per patient1.6 (1.0)1.6 (0.9)0.21
 Per lesion1.3 (0.6)1.2 (0.6)0.26
Total stent length (mm)
 Per patient26.4 (17.5)26.6 (18.2)0.78
 Per lesion20.3 (12.3)20.7 (12.9)0.38

Values shown are mean ± SD, number (%), or n/N (%).